Insider Transactions in Q1 2024 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 20
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
28,288
-11.21%
|
$396,032
$14.29 P/Share
|
|
Feb 20
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
22,802
-10.85%
|
$319,228
$14.11 P/Share
|
|
Feb 20
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
12,053
-14.19%
|
$168,742
$14.11 P/Share
|
|
Feb 20
2024
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
24,888
-10.54%
|
$348,432
$14.11 P/Share
|
|
Feb 20
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
14,295
-21.28%
|
$200,130
$14.12 P/Share
|
|
Feb 17
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,788
+17.2%
|
-
|
|
Feb 17
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
51,029
+19.54%
|
-
|
|
Feb 17
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,788
+18.11%
|
-
|
|
Feb 17
2024
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
54,415
+18.73%
|
-
|
|
Feb 17
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,613
+31.3%
|
-
|
|
Feb 14
2024
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
58,356
-24.31%
|
$875,340
$15.01 P/Share
|
|
Feb 14
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
40,855
-20.43%
|
$612,825
$15.01 P/Share
|
|
Feb 14
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
39,886
-37.61%
|
$598,290
$15.01 P/Share
|
|
Feb 14
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
28,171
-28.22%
|
$422,565
$15.01 P/Share
|
|
Feb 11
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+37.54%
|
-
|
|
Feb 11
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+30.44%
|
-
|
|
Feb 11
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+36.13%
|
-
|
|
Feb 11
2024
|
Thomas Andrew Crockett CEO |
BUY
Grant, award, or other acquisition
|
Direct |
122,500
+33.79%
|
-
|
|
Feb 08
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
29,747
+0.61%
|
$416,458
$14.7 P/Share
|
|
Feb 07
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
51,827
+1.07%
|
$725,578
$14.56 P/Share
|
|
Feb 06
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
4,474
+0.09%
|
$62,636
$14.74 P/Share
|
|
Feb 01
2024
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
10,000
-3.94%
|
$160,000
$16.5 P/Share
|
|
Jan 30
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
88,099
+1.83%
|
$1,233,386
$14.47 P/Share
|
|
Jan 29
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
80,600
+1.7%
|
$1,128,400
$14.22 P/Share
|
|
Jan 26
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
4,174
+0.09%
|
$50,088
$12.98 P/Share
|
|
Jan 25
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
7,030
+0.15%
|
$84,360
$12.73 P/Share
|
|
Jan 24
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
20,686
+0.45%
|
$248,232
$12.44 P/Share
|
|
Jan 23
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
10,897
+0.24%
|
$130,764
$12.54 P/Share
|
|
Jan 22
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
67,546
+1.47%
|
$810,552
$12.55 P/Share
|
|
Jan 19
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.56%
|
$300,000
$12.43 P/Share
|
|
Jan 18
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
39,680
+0.89%
|
$476,160
$12.51 P/Share
|
|
Jan 17
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
78,925
+1.76%
|
$947,100
$12.6 P/Share
|
|
Jan 16
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
19,599
+0.45%
|
$235,188
$12.73 P/Share
|
|
Jan 11
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
6,647
+0.15%
|
$79,764
$12.68 P/Share
|
|
Jan 11
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
22,679
-36.28%
|
$294,827
$13.03 P/Share
|
|
Jan 10
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
47,700
+1.1%
|
$572,400
$12.67 P/Share
|
|
Jan 09
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
20,816
+0.49%
|
$249,792
$12.56 P/Share
|
|
Jan 09
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
100
-0.16%
|
$1,300
$13.0 P/Share
|
|
Jan 08
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
69,184
+1.61%
|
$830,208
$12.44 P/Share
|
|
Jan 08
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
17,221
-21.57%
|
$223,873
$13.01 P/Share
|
|
Jan 04
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
41,764
+1.0%
|
$501,168
$12.11 P/Share
|
|
Jan 03
2024
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
17,605
+0.43%
|
$211,260
$12.2 P/Share
|